A new NIH grant could lead to a potential treatment for obesity-related diseases. Preliminary studies show that controlling a specific gene pathway can prevent long-term inflammation and its associated diseases.
Eastern Virginia Medical School researchers have identified a potential novel treatment strategy for the social impairment of people with Autism Spectrum Disorders. The medication, D-Cycloserine, showed promising effects in resolving the BALB/c mouse's deficits of sociability.
Researchers found that patients with pectus excavatum have reduced chest wall motion near the deformity and compensate by using abdominal muscles to draw in more air. The study suggests these patients may experience shortness of breath and easy fatigability due to the dysfunctional upper chest wall motion.
A team of researchers has isolated a molecule that can shut down a dysfunctional immune response, causing deadly conditions like hemorrhagic shock, delayed heart attack deaths, and rheumatoid arthritis joint destruction. The discovery marks a significant step toward clinical application, with the potential to save lives.
Scientists from EVMS have identified STAT4 as a key factor in the development of Type 2 diabetes and other cardiovascular diseases. Eliminating STAT4 in rodent models reduced atherosclerosis, and a high-fat diet study showed that excess STAT4 leads to inflamed fat production.
Researchers at EVMS Strelitz Diabetes Center have received a $1.076 million grant from the Department of Defense to develop new treatments for Type 1 diabetes, focusing on regeneration of insulin-producing beta cells and neutralizing the immune system's attack. The goal is to create a functional cure using a combination therapy regimen.
A new study published by researchers at Eastern Virginia Medical School has identified a protein-based enzyme called 12-Lipoxygenase (12-LO) as a key player in the development of Type 1 diabetes. The enzyme produces specific lipids that cause inflammation and lead to beta cell death, highlighting a potential target for new therapies.
A harmless shard from a childhood virus's shell may halt the complement response, a primordial part of the immune system that kills oxygen-deprived victims. This discovery could help save soldiers' lives and reduce brain damage caused by reperfusion injury.
Scientists at Eastern Virginia Medical School have identified a vital step in the development of Type 1 diabetes and hope to develop a novel therapeutic approach by blocking an enzyme called 12-LO. Preliminary results are promising, and further research is underway.
A new study confirms that texting while driving can be deadly, as teens using a driving simulator displayed significant slowing, weaving, and lane changes. The study highlights the risks of distracted driving for both drivers and pedestrians.
A unique drug combination, Lisofylline and Islet Neogenesis Associated Protein peptide, has shown promising results in reversing Type 1 diabetes in diabetic mice. The study found that the combination led to a remission rate of 70% in mice with high blood glucose levels.
AIDS researcher Dr. Edward Johnson has received a $1.8M NIH grant to study the molecular mechanics of progressive multifocal leukoencephalopathy (PML), a brain disease that kills four percent of AIDS patients worldwide. The research aims to understand how the JC virus causes PML, which can occur even in patients with well-managed AIDS.
Researchers demonstrated the safety and effectiveness of continuous-use oral contraceptives eliminating menstrual cycles in a study published in Contraception. Healthy women between 18-49 years old showed significant relief from menstrual cycle symptoms without breaks or placebos.
Scientists are researching ways to reduce radiation-induced brain damage for Mars missions, which could lead to new treatments for conditions like Alzheimer's disease. The research project is part of a $14-million study funded by NASA to determine the human brain's maximum safe cosmic radiation dose.
A new oral vaccine, Rotateq, has been shown to virtually eliminate the most severe cases of rotavirus, a common childhood virus. The vaccine nearly eliminated serious rotavirus-related gastroenteritis and reduced hospital admissions by 96%.